p38 MAP Kinase Inhibitor Ⅵ

CAS No. 421578-46-3

p38 MAP Kinase Inhibitor Ⅵ( —— )

Catalog No. M36102 CAS No. 421578-46-3

p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 180 In Stock
10MG 275 In Stock
25MG 465 In Stock
50MG 638 In Stock
100MG 901 In Stock
200MG Get Quote In Stock
500MG 1795 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    p38 MAP Kinase Inhibitor Ⅵ
  • Note
    Research use only, not for human use.
  • Brief Description
    p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
  • Description
    p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24%.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    421578-46-3
  • Formula Weight
    332.42
  • Molecular Formula
    C16H13FN2OS2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=C(C)C2=C(S1)N=CN=C2SCC(=O)C1=CC=C(F)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cheeseright TJ, et al. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. J Med Chem. 2009 Jul 23;52(14):4200-9.?
molnova catalog
related products
  • HPK1-IN-7

    HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).

  • ZINC05007751

    ZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.

  • SKLB-163

    SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.